Improving endothelial function

Why the vessel lining matters

The endothelium is the single-cell lining inside every blood vessel; it controls how vessels relax, how leaky they are, and how easily blood clots. In long COVID it often stays inflamed and dysfunctional long after the infection, which is one reason the same fault can surface as breathlessness with a normal scan, a strained heart, and a tendency to microclots. The full picture is on the endothelial dysfunction page.

Is there an objective measure of severity?

Yes — several, though there is no single validated clinical severity score, and a lower value means worse function:

• Flow-mediated dilation (FMD) — the reference functional test. Ultrasound measures how much the brachial artery widens after a blood-pressure cuff is released; the widening depends on nitric oxide release, so a smaller % FMD reflects worse function. It is real but operator-dependent.
• Reactive Hyperemia Index (RHI / EndoPAT) — a finger-cuff version (reported as LnRHI) that is more operator-independent. About a third of people with post-COVID syndrome show a diminished RHI.
• Blood biomarkers — circulating endothelial cells, endothelial microvesicles, von Willebrand factor, soluble adhesion molecules (sVCAM-1, sICAM-1, E-selectin), and glycocalyx markers such as syndecan-1. These index injury and activation rather than giving a clean severity number.

Your site treats these honestly on the endothelial biomarkers and flow-mediated dilation page: they show abnormalities in long COVID but remain research-grade and are not yet validated to guide an individual’s care.¹³

What has been tried to improve it

Most evidence is early, small, and not yet long-COVID-specific. In rough order of how directly it has been tested in long COVID:

• Sulodexide — a glycocalyx-protecting agent. In the randomized long-COVID TUN-EndCOV study it improved endothelial function and reduced chest pain and palpitations versus no treatment. The most direct positive signal so far.
• Statins, often with an ARB — improved symptoms in long-COVID cohorts and support endothelial function generally; several glycocalyx-targeted agents (Endocalyx, low-molecular-weight heparin) are in active trials.
• Enhanced external counterpulsation (EECP) — inflatable leg cuffs timed to the heartbeat; markedly improved FMD in coronary disease and is now being studied in long COVID.
• Physical activity — classically improves endothelial function, but this is the safety landmine in long COVID. If post-exertional malaise is present, graded exercise can cause lasting harm, so pacing comes first. This is not a “push through to fix your vessels” situation.
• Standard vascular-risk control — blood pressure, lipids, glucose, and not smoking all protect the endothelium; investigational add-ons (antioxidants, nitric-oxide substrates such as L-arginine/L-citrulline, hyperbaric oxygen) remain low-certainty.

Note that anticoagulation / antiplatelet therapy targets the clotting consequence (microclots) rather than repairing the endothelium itself.²⁴

Doing it safely

Almost everything above is investigational for long COVID. None is a proven cure, doses and candidates are still being worked out, and the measures cannot yet tell an individual whether a treatment is working. Anything involving exertion must be bounded by post-exertional malaise status and pacing; medications such as sulodexide, statins, or anticoagulants carry their own risks and belong in a clinician’s hands. Use this page to ask better questions, not to self-prescribe.

References

Every reference is free to read in full.

1. Clinical implications of COVID-19-related endothelial dysfunction (JACC: Advances review).
2. Sulodexide improves endothelial dysfunction and symptoms in long COVID — TUN-EndCOV study.
3. Persistent endothelial dysfunction in COVID-19 survivors late after recovery.
4. Role of enhanced external counterpulsation (EECP) in long COVID.
5. The significance of endothelial dysfunction in long COVID.

Associated topics